Efficacy and Safety of Cilostazol for the Indication of CSPS

Korea Otsuka Pharmaceutical Co., Ltd.650 enrolled

Overview

This is a multicenter, open-label, prospective study of cilostazol use for prevention of recurrence in patients with cerebral infarction.

This is a multicenter, open-label, prospective study of cilostazol use to prevention of recurrence in patients with cerebral infarction. Qualified patients will be treated with cilostazol by physician's assessment. This study will be continued for 4 years. More than 600 patients for 4 years.

Study Type

OBSERVATIONAL

Enrollment

650

Conditions

Cerebral Infarction

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with an experience of cerebral infarction and having a purpose for prevention of recurrence of cerebral infarction. * Age: more than 18 years of age Exclusion Criteria: * Unqualified patients judged by study investigator(s)

Locations (1)

Asan Medical Center

Seoul, South Korea

Outcomes

Primary Outcomes

1)Efficacy:Recurrence of cerebral infarction 2)Safety:Adverse Event

Time frame: 3M

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.